The landscape of cancer care has undergone a profound transformation over the past two decades. Once dominated by the triad of surgery, chemotherapy, and radiotherapy, oncology has entered an era increasingly defined by molecular precision and targeted therapeutics. These advances have not diminished the role of surgery; rather, they have reshaped it—demanding a re-evaluation of surgical timing, intent, and integration within multidisciplinary care. Targeted therapies, guided by tumor biology and genetic profiling, have introduced unprecedented specificity in cancer treatment. Agents directed at molecular pathways now offer the ability to downstage tumors, convert unresectable disease into operable conditions, and, in selected cases, achieve durable control without immediate surgical intervention. This evolution challenges the traditional paradigm in which surgery was often the first and most definitive step in management. For the modern oncologic surgeon, this shift necessitates a deeper engagement with tumor biology. Decision-making is no longer based solely on anatomical resectability but increasingly on molecular characteristics, response to systemic therapy, and predicted disease trajectory. The question is no longer simply “Can this tumor be removed?” but rather “Should it be removed now, later, or at all?” Neoadjuvant targeted therapy exemplifies this transformation. In malignancies such as gastrointestinal stromal tumors, breast cancer, and select lung cancers, preoperative systemic treatment has demonstrated the capacity to reduce tumor burden, facilitate organ-preserving surgery, and improve resectability. However, these advantages introduce new complexities. Determining optimal duration, assessing response, and identifying the point of maximal therapeutic benefit require close coordination between surgical and medical oncology teams. Equally significant is the emergence of non-operative or minimally invasive management strategies in carefully selected patients. Exceptional responders to targeted therapy may achieve disease control that challenges the necessity of immediate surgery. While such approaches remain investigational and must be applied with caution, they underscore a broader shift: surgery is no longer an isolated intervention, but one component of a dynamic and individualized treatment continuum. This evolving paradigm reinforces the centrality of multidisciplinary care. Tumor boards must function not as sequential decision-making forums, but as platforms for integrated strategy. Surgeons must actively contribute—not only technical expertise, but also a nuanced understanding of how operative intervention aligns with systemic and personalized therapies. Leadership in this context is defined by collaboration, adaptability, and critical judgment. Training and education must evolve in parallel. For surgical residents, familiarity with molecular oncology, clinical trials, and systemic therapies is no longer optional. Competency now extends beyond operative skill to include interpretation of genomic data and an understanding of targeted treatment pathways. For practicing consultants, continuous professional development is essential to remain aligned with rapidly advancing evidence. Despite these advances, the enduring value of surgery must be reaffirmed. Complete surgical resection remains the cornerstone of cure for many solid malignancies. Targeted therapies, while transformative, most often function as adjuncts—enhancing surgical outcomes rather than replacing operative intervention. The challenge lies in identifying the right patient, the right timing, and the right sequence. Important limitations persist. Resistance to targeted therapy, heterogeneity of response, and issues of accessibility and cost continue to shape real-world outcomes. Overreliance on systemic therapy without clearly defined surgical endpoints risks disease progression or the loss of curative opportunity. A balanced, evidence-based approach remains imperative. As we navigate this era of precision oncology, the role of the surgeon is not diminished but expanded. The oncologic surgeon must function as a strategist—integrating molecular insights, systemic therapies, and operative expertise into cohesive, patient-centered care. This demands not only technical excellence but also intellectual flexibility and interdisciplinary engagement. In conclusion, oncologic surgery in the era of targeted therapy represents a paradigm of integration rather than replacement. The scalpel remains indispensable, but its application is now guided by biology, data, and collaboration. The identity of the surgeon is evolving—from operator to orchestrator of care. The future of surgery will not be defined solely by what we remove, but by how thoughtfully we intervene. In embracing this shift, we do not diminish the legacy of the scalpel; we elevate it within a broader, more precise, and more humane vision of cancer care.
Chintamani (Tue,) studied this question.